Sunday, May 10, 2009
Friday, May 8, 2009
Saturday, May 2, 2009
Intel chart... 200 dma around the corner
the 200 dma average is the big red line coming down from the top...
Friday, May 1, 2009
Update and chart I am watching
sold MS +20% CX+1% partial X +8% TWB +11% and added to my CELG. CELG is absolutely getting murdered but with a company that is growing at a 20-30% pace with a killer pipeline (VIDAZA and REVLMID). It was downgraded today by Credit Suisse and was down 7%. It is in a horrific downtrend and down under the 50dma but if this rally continues biotechs will perk up sooner or later I feel. I am going to add some puts Monday for downside protection. GMXR is a stock looking up. It broke out once and looking to carry this momentum up. Volume is up huge. Its above the 10/20/50 dma and with the 200dma way up around $30 this stock does not have much resistance. I will look to open a position here on the next down day with natural gas seeming to have found somewhat of a base
Thursday, April 30, 2009
DE chart
]
current holdings
DO X CAT DE CTIC CTIC calls CX CX puts CLF puts PCX CELG BP INTC MS zero cash
current holdings
DO X CAT DE CTIC CTIC calls CX CX puts CLF puts PCX CELG BP INTC MS zero cash
Wednesday, April 22, 2009
Market still trending up here...
Current Portfolio (biggest investment to smallest)
DE DO X JPM JEC AGU AKAM CLF PCU CX MDR KBR
Will be looking to take profits off the table tomorrow on
DE CLF CX
Tuesday, April 21, 2009
Buys on dippage
Bought the pullback. Just call me "Dumptruck Balls". Anywho here is the list
CX $7.81
JPM $31.15 added to position
CLF $19.05 (sold friday for $21.44 rebought today)
KBR $15.22
PCU $19.41
DE $37
CTIC$0.30 sold stock bought jan 2010 $2.50 calls
also found a cool site for chart work... http://www.bestfreecharts.com
Thursday, April 16, 2009
took some profits today...
sold CSCO +10% JPM +8% VMW +2.5% EBAY -3% STT-2%
portfolio
DO X JPM AKAM JEC MDR CTIC CLF
added JEC $44.72 and MDR $16.69
JEC (Jacobs Engineering Group)
Jacobs Engineering Group Inc., incorporated on January 8, 1987, is engaged in providing a range of technical, professional, and construction services to a number of industrial, commercial, and governmental clients globally. The Company provides four categories of services: project services, which include engineering, design, architectural, and similar services; process, scientific, and systems consulting services, which includes services performed in connection with a range of scientific testing, analysis, and consulting activities; construction services, which encompasses traditional field construction services, as well as modular construction activities, and includes direct-hire construction and construction management services, and operations and maintenance services, which includes services performed in connection with operating large, complex facilities on behalf of clients, as well as services involving process plant maintenance.
Project Services
The Company employs all of the engineering, design, architectural, and related disciplines necessary to design and engineer modern process plants (including projects for clients in the chemicals and polymers; pharmaceuticals and biotechnology; oil and gas; refining; food and consumer products; and basic resources industries); buildings (including facilities for clients in the health care; education; and criminal justice markets, as well as other buildings for clients in the private sector); infrastructure projects (including highways, roads, bridges, and other transportation systems; water and wastewater treatment plants; water resources facilities; and other similar plants and facilities); technology and manufacturing facilities (for clients in the aerospace; automotive; defense; semiconductor; and electronics industries); consumer products manufacturing facilities; pulp and paper plants; and other facilities. It also employs scientific, technical, and program management capabilities necessary to provide program integration, testing, and evaluation services for clients in the defense and aerospace industries; for the United States Department of Defense (DoD) in support of information systems for weapons acquisition centers; for the National Aeronautics and Space Administration (NASA) for aerospace, testing, and propulsion systems and facilities; and for various agencies of the United States federal government in support of environmental programs.
Process, Scientific and Systems Consulting
The Company provides a range of consulting services, including performing pricing studies, market analyses, and financial projections necessary in determining the feasibility of a project; performing gasoline reformulation modeling; analyzing and evaluating layout and mechanical designs for complex processing plants; analyzing automation and control systems; analyzing, designing, and executing biocontainment strategies; developing and performing process protocols with respect to the United States Food and Drug Administration-mandated qualification and validation requirements; providing consultation on proposed railway and airport expansion projects; and performing geological and metallurgical studies.
Also included in this service category are the revenues relating to professional and program management services required assisting clients (such as the United States federal government and its agencies) in a range of defense and aerospace related programs. Such services are more technical and scientific in nature than other project services and may involve such tasks as supporting the development and testing of conventional weapons systems; weapons modeling and simulations; computer systems development, maintenance, and support; evaluation and testing of mission-critical control systems; and other technical programs and tasks.
Construction
The Company provides field construction services to private and public sector clients in virtually all of the industry groups and markets to which it provides project services. In the area of environmental remediation and restoration, the Company provide environmental remedial construction services for a variety of public and private sector clients. It also provides its clients with modular construction technology. The modular construction technology is an advanced form of engineering and design, off-site fabrication and assembly, and field erection. The field construction activities are focussed on those construction projects for which it perform much of the related engineering and design work.
Operations and Maintenance (O&M)
O&M refers to all the tasks required to operate and maintain large, complex facilities on behalf of clients. The Company provides management and support services over all aspects of the operations of a facility, including managing subcontractors and other on-site personnel. Within the environmental area, O&M includes engineering and technical support services as well as program management services necessary to remediate contaminated sites. Within the aerospace and defense areas, O&M requires to provide the management and technical support services necessary to operate and maintain engine test facilities, weapons integration, and high-tech simulation and verification centers. O&M also includes process plant maintenance services, which involves all of the tasks required to keep a process plant (typically a refinery or chemical plant) in day-to-day operation.
MDR ( McDermott International Inc)
McDermott International, Inc. (MII), incorporated in 1959, is an engineering and construction company with specialty manufacturing and service capabilities. MII provides a variety of products and services to customers in the energy and power industries, including utilities and other power generators, and national oil companies, and the United States Government. MII is the parent company of the McDermott group of companies, including J. Ray McDermott, S.A. (JRMSA) and The Babcock & Wilcox Company (B&W). The Company operates in three business segments: Offshore Oil and Gas Construction, Government Operations and Power Generation Systems. On December 31, 2008, the Company’s Government Operations segment completed its acquisition of Nuclear Fuel Services, Inc., a provider of specialty nuclear fuels and related services.
Offshore Oil and Gas Construction
Offshore Oil and Gas Construction segment includes the business and operations of JRMSA, J. Ray McDermott Holdings, LLC and their respective subsidiaries. The Company through this segment supplies services primarily to offshore oil and gas field developments worldwide, including the front-end design and detailed engineering, fabrication and installation of offshore drilling and production facilities and installation of marine pipelines and subsea production systems. It also provides project management and procurement services. This segment operates in offshore oil and gas producing regions, including the United States, Mexico, Canada, the Middle East, India, the Caspian Sea and Asia Pacific.
MII operates a fleet of marine vessels used in offshore construction. The Company's principal fabrication facilities are located near Morgan City, Louisiana, in Indonesia on Batam Island, and in Dubai, United Arab Emirates. The Company also operates a portion of the Baku Deepwater Jacket Factory fabrication facility in Baku, Azerbaijan. MII fabricates a range of offshore structures, from conventional jacket-type fixed platforms to intermediate water and deepwater platform configurations employing Spar, compliant-tower and tension leg technologies, as well as floating, production, storage and off-loading (FPSO) technology. The Company’s Offshore Oil and Gas Construction segment's principal customers are businesses in the offshore oil, natural gas and hydrocarbon processing industries and other offshore construction companies.
MII competes with Allseas Marine Contractors S.A., Daewoo Engineering & Construction Co., Ltd., Global Industries Ltd., NPCC (Abu Dhabi), Heerema Group, Hyundai Heavy Industrial Co., Ltd., Kiewit Offshore Services, Ltd., Nippon Steel Corporation, Saipem S.p.A., Acergy S.A., Technip S.A. and Samsung Heavy Industries Co., Ltd.
Government Operations
Government Operations segment includes the business and operations of BWX Technologies, Inc., Babcock & Wilcox Nuclear Operations Group, Inc., Babcock & Wilcox Technical Services Group, Inc. and their respective subsidiaries. Through this segment, the Company supplies nuclear components, including the manufacture of United States Naval nuclear power systems for submarines and aircraft carriers, and provides various other services to the United States Government, including uranium processing, environmental site restoration services, and management and operating services for various United States Government-owned facilities, primarily within the nuclear weapons complex of the United States Department of Energy (DOE).
The principal areas of operation of this segment include providing precision manufactured nuclear components for the United States Government defense programs; managing and operating nuclear production facilities; managing and operating environmental management sites; managing spent nuclear fuel and transuranic waste for the DOE; providing critical skills and resources for DOE sites, and developing and deploying next-generation technology in support of United States Government programs. The Company's principal manufacturing facilities are located in Barberton, Ohio, Euclid, Ohio, Mount Vernon, Indiana, Lynchburg, Virginia and Erwin, Tennessee. In addition, it manufactures nuclear components, fuels and assemblies for government and commercial uses. It also provides uranium-based products used for medical isotopes and convert or downblend high-enriched uranium into low-enriched fuel for use in commercial reactors to generate electricity. The primary customer of its Government Operations segment is the United States Government, including its contractors.
The Company competes with Bechtel National Inc., URS Corporation, CH2M Hill, Inc., Fluor Corporation, Lockheed Martin Corporation, Jacobs Engineering Group, Inc. and EnergySolutions, Inc.
Power Generation Systems
Power Generation Systems includes the business and operations of Babcock & Wilcox Power Generation Group, Inc. (B&W PGG), Babcock & Wilcox Nuclear Power Generation Group, Inc. (B&W NPG) and their respective subsidiaries. This segment supplies fossil-fired steam generating systems, replacement commercial nuclear steam generators, environmental equipment and components, and related services to customers around the world. It designs, engineers, manufactures and services large utility and industrial power generation systems, including boilers used to generate steam in electric power plants, pulp and paper making, chemical and process applications and other industrial uses. Its manufacturing facilities are located in Barberton, Ohio; Lynchburg, Virginia; West Point, Mississippi; Lancaster, Ohio; Copley, Ohio; Cambridge, Ontario, Canada; Esbjerg, Denmark; Melville, Saskatchewan, Canada, and Jingshan, Hubei, China. The Power Generation Systems segment’s major customers are utilities.
Rock on! Kidd out...
portfolio
DO X JPM AKAM JEC MDR CTIC CLF
added JEC $44.72 and MDR $16.69
JEC (Jacobs Engineering Group)
Jacobs Engineering Group Inc., incorporated on January 8, 1987, is engaged in providing a range of technical, professional, and construction services to a number of industrial, commercial, and governmental clients globally. The Company provides four categories of services: project services, which include engineering, design, architectural, and similar services; process, scientific, and systems consulting services, which includes services performed in connection with a range of scientific testing, analysis, and consulting activities; construction services, which encompasses traditional field construction services, as well as modular construction activities, and includes direct-hire construction and construction management services, and operations and maintenance services, which includes services performed in connection with operating large, complex facilities on behalf of clients, as well as services involving process plant maintenance.
Project Services
The Company employs all of the engineering, design, architectural, and related disciplines necessary to design and engineer modern process plants (including projects for clients in the chemicals and polymers; pharmaceuticals and biotechnology; oil and gas; refining; food and consumer products; and basic resources industries); buildings (including facilities for clients in the health care; education; and criminal justice markets, as well as other buildings for clients in the private sector); infrastructure projects (including highways, roads, bridges, and other transportation systems; water and wastewater treatment plants; water resources facilities; and other similar plants and facilities); technology and manufacturing facilities (for clients in the aerospace; automotive; defense; semiconductor; and electronics industries); consumer products manufacturing facilities; pulp and paper plants; and other facilities. It also employs scientific, technical, and program management capabilities necessary to provide program integration, testing, and evaluation services for clients in the defense and aerospace industries; for the United States Department of Defense (DoD) in support of information systems for weapons acquisition centers; for the National Aeronautics and Space Administration (NASA) for aerospace, testing, and propulsion systems and facilities; and for various agencies of the United States federal government in support of environmental programs.
Process, Scientific and Systems Consulting
The Company provides a range of consulting services, including performing pricing studies, market analyses, and financial projections necessary in determining the feasibility of a project; performing gasoline reformulation modeling; analyzing and evaluating layout and mechanical designs for complex processing plants; analyzing automation and control systems; analyzing, designing, and executing biocontainment strategies; developing and performing process protocols with respect to the United States Food and Drug Administration-mandated qualification and validation requirements; providing consultation on proposed railway and airport expansion projects; and performing geological and metallurgical studies.
Also included in this service category are the revenues relating to professional and program management services required assisting clients (such as the United States federal government and its agencies) in a range of defense and aerospace related programs. Such services are more technical and scientific in nature than other project services and may involve such tasks as supporting the development and testing of conventional weapons systems; weapons modeling and simulations; computer systems development, maintenance, and support; evaluation and testing of mission-critical control systems; and other technical programs and tasks.
Construction
The Company provides field construction services to private and public sector clients in virtually all of the industry groups and markets to which it provides project services. In the area of environmental remediation and restoration, the Company provide environmental remedial construction services for a variety of public and private sector clients. It also provides its clients with modular construction technology. The modular construction technology is an advanced form of engineering and design, off-site fabrication and assembly, and field erection. The field construction activities are focussed on those construction projects for which it perform much of the related engineering and design work.
Operations and Maintenance (O&M)
O&M refers to all the tasks required to operate and maintain large, complex facilities on behalf of clients. The Company provides management and support services over all aspects of the operations of a facility, including managing subcontractors and other on-site personnel. Within the environmental area, O&M includes engineering and technical support services as well as program management services necessary to remediate contaminated sites. Within the aerospace and defense areas, O&M requires to provide the management and technical support services necessary to operate and maintain engine test facilities, weapons integration, and high-tech simulation and verification centers. O&M also includes process plant maintenance services, which involves all of the tasks required to keep a process plant (typically a refinery or chemical plant) in day-to-day operation.
MDR ( McDermott International Inc)
McDermott International, Inc. (MII), incorporated in 1959, is an engineering and construction company with specialty manufacturing and service capabilities. MII provides a variety of products and services to customers in the energy and power industries, including utilities and other power generators, and national oil companies, and the United States Government. MII is the parent company of the McDermott group of companies, including J. Ray McDermott, S.A. (JRMSA) and The Babcock & Wilcox Company (B&W). The Company operates in three business segments: Offshore Oil and Gas Construction, Government Operations and Power Generation Systems. On December 31, 2008, the Company’s Government Operations segment completed its acquisition of Nuclear Fuel Services, Inc., a provider of specialty nuclear fuels and related services.
Offshore Oil and Gas Construction
Offshore Oil and Gas Construction segment includes the business and operations of JRMSA, J. Ray McDermott Holdings, LLC and their respective subsidiaries. The Company through this segment supplies services primarily to offshore oil and gas field developments worldwide, including the front-end design and detailed engineering, fabrication and installation of offshore drilling and production facilities and installation of marine pipelines and subsea production systems. It also provides project management and procurement services. This segment operates in offshore oil and gas producing regions, including the United States, Mexico, Canada, the Middle East, India, the Caspian Sea and Asia Pacific.
MII operates a fleet of marine vessels used in offshore construction. The Company's principal fabrication facilities are located near Morgan City, Louisiana, in Indonesia on Batam Island, and in Dubai, United Arab Emirates. The Company also operates a portion of the Baku Deepwater Jacket Factory fabrication facility in Baku, Azerbaijan. MII fabricates a range of offshore structures, from conventional jacket-type fixed platforms to intermediate water and deepwater platform configurations employing Spar, compliant-tower and tension leg technologies, as well as floating, production, storage and off-loading (FPSO) technology. The Company’s Offshore Oil and Gas Construction segment's principal customers are businesses in the offshore oil, natural gas and hydrocarbon processing industries and other offshore construction companies.
MII competes with Allseas Marine Contractors S.A., Daewoo Engineering & Construction Co., Ltd., Global Industries Ltd., NPCC (Abu Dhabi), Heerema Group, Hyundai Heavy Industrial Co., Ltd., Kiewit Offshore Services, Ltd., Nippon Steel Corporation, Saipem S.p.A., Acergy S.A., Technip S.A. and Samsung Heavy Industries Co., Ltd.
Government Operations
Government Operations segment includes the business and operations of BWX Technologies, Inc., Babcock & Wilcox Nuclear Operations Group, Inc., Babcock & Wilcox Technical Services Group, Inc. and their respective subsidiaries. Through this segment, the Company supplies nuclear components, including the manufacture of United States Naval nuclear power systems for submarines and aircraft carriers, and provides various other services to the United States Government, including uranium processing, environmental site restoration services, and management and operating services for various United States Government-owned facilities, primarily within the nuclear weapons complex of the United States Department of Energy (DOE).
The principal areas of operation of this segment include providing precision manufactured nuclear components for the United States Government defense programs; managing and operating nuclear production facilities; managing and operating environmental management sites; managing spent nuclear fuel and transuranic waste for the DOE; providing critical skills and resources for DOE sites, and developing and deploying next-generation technology in support of United States Government programs. The Company's principal manufacturing facilities are located in Barberton, Ohio, Euclid, Ohio, Mount Vernon, Indiana, Lynchburg, Virginia and Erwin, Tennessee. In addition, it manufactures nuclear components, fuels and assemblies for government and commercial uses. It also provides uranium-based products used for medical isotopes and convert or downblend high-enriched uranium into low-enriched fuel for use in commercial reactors to generate electricity. The primary customer of its Government Operations segment is the United States Government, including its contractors.
The Company competes with Bechtel National Inc., URS Corporation, CH2M Hill, Inc., Fluor Corporation, Lockheed Martin Corporation, Jacobs Engineering Group, Inc. and EnergySolutions, Inc.
Power Generation Systems
Power Generation Systems includes the business and operations of Babcock & Wilcox Power Generation Group, Inc. (B&W PGG), Babcock & Wilcox Nuclear Power Generation Group, Inc. (B&W NPG) and their respective subsidiaries. This segment supplies fossil-fired steam generating systems, replacement commercial nuclear steam generators, environmental equipment and components, and related services to customers around the world. It designs, engineers, manufactures and services large utility and industrial power generation systems, including boilers used to generate steam in electric power plants, pulp and paper making, chemical and process applications and other industrial uses. Its manufacturing facilities are located in Barberton, Ohio; Lynchburg, Virginia; West Point, Mississippi; Lancaster, Ohio; Copley, Ohio; Cambridge, Ontario, Canada; Esbjerg, Denmark; Melville, Saskatchewan, Canada, and Jingshan, Hubei, China. The Power Generation Systems segment’s major customers are utilities.
Rock on! Kidd out...
Wednesday, April 15, 2009
new spec biotech play
Today I bought CTIC $0.34 as a speculative biotech play. Only purchased 2% currently and will add along the way.
"Cell Therapeutics, Inc. (Cell Therapeutics), incorporated in 1991, develops, acquires and commercializes treatments for cancer. The Company’s research, development, acquisition and in-licensing activities concentrate on identifying and developing new, less toxic and effective ways to treat cancer. Cell Therapeutics is developing pixantrone (BBR 2778), a deoxyribonucleic acid (DNA) major groove binder with an aza-anthracenedione molecular structure, differentiating it from anthracycline chemotherapy agents. A new chemical compound for the treatment of non-Hodgkin’s lymphoma (NHL), and various other hematologic malignancies, solid tumors, and immunological disorders, pixantrone is being developed to improve activity and safety in treating cancers treated with the anthracycline family of anti-cancer agents. It is developing OPAXIO (paclitaxel poliglumex), which was previously referred to as XYOTAX, for the treatment of non-small cell lung cancer (NSCLC), and ovarian cancer. It is also developing OPAXIO for women with pre-menopausal levels of estrogen, regardless of age, who have advanced NSCLC with normal or poor performance status.
Pixantrone
Cell Therapeutics has several clinical trials with pixantrone, including a pivotal phase III trial, known as the EXTEND, or PIX301, trial of pixantrone (BBR2778) for the treatment of patients with relapsed aggressive NHL, a condition for which there are no chemotherapy drugs approved in the United States. The Company also conducted the RAPID, or PIX203, phase II study (CHOP-R vs. CPOP-R), in which pixantrone is substituted for doxorubicin in the CHOP-R regimen compared to the standard CHOP-R regimen in patients with aggressive NHL.
OPAXIO
OPAXIO (paclitaxel poliglumex, CT-2103) is the Company’s biologically enhanced chemotherapeutic agent that links paclitaxel to a biodegradable polyglutamate polymer, resulting in a new chemical entity. It is developing OPAXIO for the potential treatment of NSCLC, ovarian and other cancers. OPAXIO was designed to improve the delivery of paclitaxel to tumor tissue while protecting normal tissue from toxic side effects. Taxanes, including paclitaxel (Taxol) and docetaxel (Taxotere), is used for the treatment of various solid tumors, including non-small cell lung, ovarian, breast and prostate cancers. Paclitaxel is considered a standard-of-care in lung and ovarian cancers, where it is used.
Brostallicin
Cell Therapeutics is developing brostallicin, which is a small molecule, chemotherapeutic agent with a unique mechanism of action and composition of matter patent coverage. Data in more than 230 patients treated with brostallicin in phase I/II clinical trials reveal evidence of activity in patients with refractory cancer and patient/physician-friendly dosage and administration. A phase II study of brostallicin in relapsed/refractory soft tissue sarcoma met its pre-defined activity and safety hurdles and resulted in a first-line phase II study that is being conducted by the European Organization for Research and Treatment of Cancer (EORTC). Planned enrollment for this study was completed in August 2008. Brostallicin has also demonstrated synergy with new targeted agents, as well as established treatments in preclinical trials; consequently, it began a multi-arm combination study with brostallicin and other agents, including Avastin (bevacizumab), which was substantially completed during the year ended December 31, 2008.
Zevalin (Ibritumomab Tiuxetan)
Zevalin is a form of cancer therapy called radioimmunotherapy and is indicated for the treatment of patients with relapsed or refractory low-grade or follicular B-cell NHL, including patients with rituximab-refractory follicular NHL. It was approved by the United States Food and Drug Administration (FDA) as the first radioimmunotherapeutic agent for the treatment of NHL. It developed Zevalin from its acquisition of that product line in December 2007 until the transfer of Zevalin to RIT Oncology in December 2008. As of March 9, 2009, the Company was engaged in the process of selling its remaining 50% interest in RIT Oncology to Spectrum.
The Company competes with Bristol-Myers Squibb Co., Sanofi Aventis, Wyeth, Roche, Genentech, OSI Pharmaceuticals, Eli Lilly, Abraxis, Neopharm Inc., Telik Inc., TEVA Pharmaceuticals and PharmaMar."
http://tinyurl.com/dafho6 link for above info from Reuters
the company has filed a NDA (new drug application) to the US FDA for the pixantrone
http://tinyurl.com/cv8bad
I will play this stock on a pure speculative play. Chart seems to show support forming aroun the $0.30 area. It just received a fresh capital injection http://tinyurl.com/cv533v
"The company says it plans to present positive data from a clinical trial of that drug at the American Society of Clinical Oncology’s annual meeting in late May and early June."
Rock on!
"Cell Therapeutics, Inc. (Cell Therapeutics), incorporated in 1991, develops, acquires and commercializes treatments for cancer. The Company’s research, development, acquisition and in-licensing activities concentrate on identifying and developing new, less toxic and effective ways to treat cancer. Cell Therapeutics is developing pixantrone (BBR 2778), a deoxyribonucleic acid (DNA) major groove binder with an aza-anthracenedione molecular structure, differentiating it from anthracycline chemotherapy agents. A new chemical compound for the treatment of non-Hodgkin’s lymphoma (NHL), and various other hematologic malignancies, solid tumors, and immunological disorders, pixantrone is being developed to improve activity and safety in treating cancers treated with the anthracycline family of anti-cancer agents. It is developing OPAXIO (paclitaxel poliglumex), which was previously referred to as XYOTAX, for the treatment of non-small cell lung cancer (NSCLC), and ovarian cancer. It is also developing OPAXIO for women with pre-menopausal levels of estrogen, regardless of age, who have advanced NSCLC with normal or poor performance status.
Pixantrone
Cell Therapeutics has several clinical trials with pixantrone, including a pivotal phase III trial, known as the EXTEND, or PIX301, trial of pixantrone (BBR2778) for the treatment of patients with relapsed aggressive NHL, a condition for which there are no chemotherapy drugs approved in the United States. The Company also conducted the RAPID, or PIX203, phase II study (CHOP-R vs. CPOP-R), in which pixantrone is substituted for doxorubicin in the CHOP-R regimen compared to the standard CHOP-R regimen in patients with aggressive NHL.
OPAXIO
OPAXIO (paclitaxel poliglumex, CT-2103) is the Company’s biologically enhanced chemotherapeutic agent that links paclitaxel to a biodegradable polyglutamate polymer, resulting in a new chemical entity. It is developing OPAXIO for the potential treatment of NSCLC, ovarian and other cancers. OPAXIO was designed to improve the delivery of paclitaxel to tumor tissue while protecting normal tissue from toxic side effects. Taxanes, including paclitaxel (Taxol) and docetaxel (Taxotere), is used for the treatment of various solid tumors, including non-small cell lung, ovarian, breast and prostate cancers. Paclitaxel is considered a standard-of-care in lung and ovarian cancers, where it is used.
Brostallicin
Cell Therapeutics is developing brostallicin, which is a small molecule, chemotherapeutic agent with a unique mechanism of action and composition of matter patent coverage. Data in more than 230 patients treated with brostallicin in phase I/II clinical trials reveal evidence of activity in patients with refractory cancer and patient/physician-friendly dosage and administration. A phase II study of brostallicin in relapsed/refractory soft tissue sarcoma met its pre-defined activity and safety hurdles and resulted in a first-line phase II study that is being conducted by the European Organization for Research and Treatment of Cancer (EORTC). Planned enrollment for this study was completed in August 2008. Brostallicin has also demonstrated synergy with new targeted agents, as well as established treatments in preclinical trials; consequently, it began a multi-arm combination study with brostallicin and other agents, including Avastin (bevacizumab), which was substantially completed during the year ended December 31, 2008.
Zevalin (Ibritumomab Tiuxetan)
Zevalin is a form of cancer therapy called radioimmunotherapy and is indicated for the treatment of patients with relapsed or refractory low-grade or follicular B-cell NHL, including patients with rituximab-refractory follicular NHL. It was approved by the United States Food and Drug Administration (FDA) as the first radioimmunotherapeutic agent for the treatment of NHL. It developed Zevalin from its acquisition of that product line in December 2007 until the transfer of Zevalin to RIT Oncology in December 2008. As of March 9, 2009, the Company was engaged in the process of selling its remaining 50% interest in RIT Oncology to Spectrum.
The Company competes with Bristol-Myers Squibb Co., Sanofi Aventis, Wyeth, Roche, Genentech, OSI Pharmaceuticals, Eli Lilly, Abraxis, Neopharm Inc., Telik Inc., TEVA Pharmaceuticals and PharmaMar."
http://tinyurl.com/dafho6 link for above info from Reuters
the company has filed a NDA (new drug application) to the US FDA for the pixantrone
http://tinyurl.com/cv8bad
I will play this stock on a pure speculative play. Chart seems to show support forming aroun the $0.30 area. It just received a fresh capital injection http://tinyurl.com/cv533v
"The company says it plans to present positive data from a clinical trial of that drug at the American Society of Clinical Oncology’s annual meeting in late May and early June."
Rock on!
Tuesday, April 14, 2009
VMW
VMW looking ready to move up still. A close above $31.80 would give the 200 ema as support and I would be looking to buy.
JPM
Poised to carry this rally further with good earnings and since I see no reason to believe that they should disappoint, I will hold. Chart looks solid with it above the 200/50/20 emas and buidling. Not a whole lot of resistance in the way either.
Monday, April 13, 2009
todays trade...
Here are my early morning buys and since the rally seems to be continuing I will hold them. I am fully invested currently and I am adding to my DO and X positions tomorrow when I add 6.5% cash to my account.
SGR
BOUGHT
CASH
$27.42
JPM
BOUGHT
CASH
$33.7598
JPM
BOUGHT
CASH
$33.3598
STT
BOUGHT
CASH
$35.7898
EBAY
BOUGHT
CASH
$14.5098
CLF
BOUGHT
CASH
$19.17
Portfolio currently-- DO X JPM STT CLF SGR AKAM EBAY CELG CSCO SQNM
SGR
BOUGHT
CASH
$27.42
JPM
BOUGHT
CASH
$33.7598
JPM
BOUGHT
CASH
$33.3598
STT
BOUGHT
CASH
$35.7898
EBAY
BOUGHT
CASH
$14.5098
CLF
BOUGHT
CASH
$19.17
Portfolio currently-- DO X JPM STT CLF SGR AKAM EBAY CELG CSCO SQNM
Sunday, April 12, 2009
Diamond Offshore Chart
Earnings this week
key earnings this week
BLK -- Monday
GS INTC JNJ -- Tuesday
ABT -- Wednesday
JPM AMLN -- Thursday
GE C -- Friday
Financials have been, along with tech, carrying this market higher. I am struggling with myself to decide if I want to buy more JPM pre earnings. I am looking for GS to post a fabulous quarter also and since they report before JPM we could see the financials continue up if they do. SO I think I am looking to gamble come Monday and buy some BLK pre earnings and see if I can win some nachos. Rock on. Gotta hit the Business Law books. Test tuesday.
Saturday, April 11, 2009
Stocks in my view.
Portfolio -- DO X JPM STT AKAM CSCO SQNM
Now I will analyze and post why I am holding each individual stock.
JPM -- best in business in the banking industry but not why I am holding. They report earnings Thursday and if WFC showed us anything its that banks have made money this quarter and I look for this to show in JPM come thursday. I own some with a 27% gain currently so I am looking to add to that position before thursday. They are expected to post a profit of $0.31/share. The chart looks pretty solid with the stock above the 10/20/50 day sma.
More to come.
Now I will analyze and post why I am holding each individual stock.
JPM -- best in business in the banking industry but not why I am holding. They report earnings Thursday and if WFC showed us anything its that banks have made money this quarter and I look for this to show in JPM come thursday. I own some with a 27% gain currently so I am looking to add to that position before thursday. They are expected to post a profit of $0.31/share. The chart looks pretty solid with the stock above the 10/20/50 day sma.
More to come.
Thursday, April 9, 2009
Today was Ginormus...
WFC blew earnings out of the water with a surprise and off to the races we went. Out the gate JPM STT MSS were up 6-8% and I held feeling it was going to be a monster day cause we were showing strength everyone. It took me a while because JAVA was downgraded and SGR reported dismal earnings. But I sold JAVA to break even at $6.56 and SGR -2.5% then sold CX +13% MS +7.4% EBAY +7.6% CLF +1% then still holding JPM +19% STT +13% X+17% DO+9.5% CSCO +4% SQNM +7% AKAM +1%
Portfolio JPM STT X DO CSCO SQNM AKAM
CASH 33%
Tuesday, April 7, 2009
Well Well Well...
Today was overall a buying oppurtunity for me. I was sitting with a handful of cash and put it to work quick. I bought a few positions, added to some, and sold one.
|
Monday, April 6, 2009
Why oh why?
Do I want to buy BAC? but I want to for the simple purposes this is going to be a behemoth of a bank and man are they going to make some money and the trend looks good but earnings may kill this and I dont want to buy to early. SOOOooo, I will buy a 2% chunk tomorrow and more after earnings. I also am looking to add to JPM SGR CSCO CLF DO CELG on pullbacks.
Here is a link to the vote for Wednesday on the uptick rule or a modified version of it. http://www.reuters.com/article/marketsNews/idUSN0635718420090407
Here is a link to the vote for Wednesday on the uptick rule or a modified version of it. http://www.reuters.com/article/marketsNews/idUSN0635718420090407
Porfolio
TECH-- AKAM 9% JAVA 4% CSCO 3% CX 3% VMW 2.5% EBAY 2.5%
OIL-- DO 7.5%
BIOTECH-- SQNM 5.5% AMLN 2%
MINERALS/METALS -- CLF 3.5% X 8.5%
FINNIES -- MS 3.5% JPM 2.5%
INDUSTRIALS-- SGR 2.5%
AND WILL BUY MORE WITH ANY WEAKNESS
IN CELG MS JPM CLF FCX SQNM AMLN
OIL-- DO 7.5%
BIOTECH-- SQNM 5.5% AMLN 2%
MINERALS/METALS -- CLF 3.5% X 8.5%
FINNIES -- MS 3.5% JPM 2.5%
INDUSTRIALS-- SGR 2.5%
AND WILL BUY MORE WITH ANY WEAKNESS
IN CELG MS JPM CLF FCX SQNM AMLN
Bought in...
Friday, April 3, 2009
Small buy
Akamai Technologies (AKAM) downgraded today and felt it down $1.49 (7%). I bought a 10% position at the close $20.10 a share
"NEW YORK - Akamai Technologies Inc. shares fell Friday after a Citi Investment Research analyst downgraded the Web traffic-management services provider's stock to "Hold" from "Buy," saying the stock is nearing his $22 price target.
The move is a valuation call, and means the analyst does not recommend buying the shares at their current price
Akamai shares fell $1.71, or 7.9 percent, to $19.84 in afternoon trading.
In a note to clients, Citi analyst Mark Mahaney said he still sees Akamai as a core Web stock, but would be more interested in the shares if they were trading below $18, since that would offer 20 percent-plus upside to his price target.
He does see competition increasing for the company, though, noting that Limelight Networks Inc. recently unveiled a whole site delivery product called LimelightSITE.
"While it is too early to tell, we do believe Limelight's new product could be an incremental threat to Akamai's commerce business, which accounted for more than 30 percent of revenue in Q4," he wrote."
Company Background
Akamai Technologies, Inc. (Akamai) provides services for accelerating and improving the delivery of content and applications over the Internet, from live and on-demand streaming videos to conventional content on Websites, to tools that help people transact business. The Company's solutions are designed to help businesses, government agencies and other enterprises. It offers services and solutions for digital media and software distribution and storage, content and application delivery, application performance services and other specialized Internet-based offerings. In November 2008, Akamai completed its acquisition of aCerno, Inc.
up 43% YTD and with the 7% pullback I feel it will continue into the tech strength.
Thursday, April 2, 2009
Took profits today
Took some profits today with the S&P up 3%
Sold all FCX MS JPM STT CELG and some X and DO
Portfolio 8% DO 10% X 72% Cash
I'll wait for a pullback to buy back in some. I have to take profits or I'll watch them disappear. Good luck all. Plus I have some free trades built up so no transaction fee just have to wait for settlement.
Sold all FCX MS JPM STT CELG and some X and DO
Portfolio 8% DO 10% X 72% Cash
I'll wait for a pullback to buy back in some. I have to take profits or I'll watch them disappear. Good luck all. Plus I have some free trades built up so no transaction fee just have to wait for settlement.
Wednesday, April 1, 2009
Well well well
Tomorrow is the day. We shall see what the FASB votes in the morning before the bell. Control of the market tomorrow is in their hands. I purchased some STT today at the close and added to my CELG position @ $37.80. This is a quality run company which lowered guidance and got absolutely demolished because of it. Demolished I say... down 13.36% but what is weird is that it was only down 0.5% ($0.17) from open to close. But the MACD crossedover it hit its 52 week low today so I would not recommend anyone to buy in unless you have a long term outlook. On the other hand, JPM and MS have been burning up the road and I will prolly bail tomorrow when they announce the change to M2M. And this is carrying the market up right now.
Portfolio
DO JPM MS STT CELG X FCX
Boy did I miss the CLF train... but this puppy could go higher. If it breaks $19.50ish we could see $20-$21.50 easy.
Monday, March 30, 2009
Sold out
Well overal today was a plus. Sold most my positions at the open. And rebought around 780 on the S&P which turned out to be gold at the close.
Sold DO $64.31 CLF $17 CELG $45.55
then around 115 bought DO $63.92 MS$22 JPM$25 CELG $45 added FCX $38.37 and with QID making a gain today on a 3% market down day. I lost 0.1%. With the close below the 50 DMA on the S&P we could be tunring back bearish. I will be watching this closely. DO closed today $65
https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEg40cYOn8kkcbCYBavIzMalYCnK2eWRZagm7dNr4z-Rrl9pL8PclMnxeOFi3dDlOHcGoLed6QO71gTvOqYEs8Y5G1llHyg5KIYrR5n7ukGOvaSmv5sew4q6crSu-JlVaANggxMvlOoCtjY/s1600-h/stock_charts_1_03-30-09.png
May tomorrow be another day...
QOD-- "Yea, talking monkey! Ugly littler suckers. Only say FICUS!" Gay Perry (AKA Val Kilmer in Kiss Kiss Bang Bang)
Sold DO $64.31 CLF $17 CELG $45.55
then around 115 bought DO $63.92 MS$22 JPM$25 CELG $45 added FCX $38.37 and with QID making a gain today on a 3% market down day. I lost 0.1%. With the close below the 50 DMA on the S&P we could be tunring back bearish. I will be watching this closely. DO closed today $65
https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEg40cYOn8kkcbCYBavIzMalYCnK2eWRZagm7dNr4z-Rrl9pL8PclMnxeOFi3dDlOHcGoLed6QO71gTvOqYEs8Y5G1llHyg5KIYrR5n7ukGOvaSmv5sew4q6crSu-JlVaANggxMvlOoCtjY/s1600-h/stock_charts_1_03-30-09.png
May tomorrow be another day...
QOD-- "Yea, talking monkey! Ugly littler suckers. Only say FICUS!" Gay Perry (AKA Val Kilmer in Kiss Kiss Bang Bang)
Sunday, March 29, 2009
Futures dropping...
Futures
DOW -81
SP -10
NAS -14
This could drop us at the open to the critical 800 level on the SP. If we close below there, we will test the lows. I will hold my QID til we either hit or break SP666. Then I will buy JPM MS. Rock on twizzlestix
Friday, March 27, 2009
been out a bit...
Overall, Revamped my position currenly here is the portfolio:
QID 18% (short the Q's)
CELG 14%
DO 25%
X 5%
FCX 19%
CLF 14%
CASH 5%
I am also going to buy more X come Tuesday and will look to lighten up my mineral position with FCX and CLF both in the portfolio but both have been on fire. As long as the S&P stays above 800 on the close I will stay long. We break it on the close. I will close all my longs and go short. Finnies are still to be had and I will be looking to buy MS JPM on any weakness. Jamie Dimon commented today that JPM is having a tough coupple months and man would I love to see a bad quarter to get back in this puppy. Anything bad will turn the market south with the Finnies leading us out with Tech also. GL peeps!
Target buys
MS below $19
JPM below $20
here is the link for the Dimon comment
http://www.reuters.com/article/marketsNews/idUSN2735918020090327
QID 18% (short the Q's)
CELG 14%
DO 25%
X 5%
FCX 19%
CLF 14%
CASH 5%
I am also going to buy more X come Tuesday and will look to lighten up my mineral position with FCX and CLF both in the portfolio but both have been on fire. As long as the S&P stays above 800 on the close I will stay long. We break it on the close. I will close all my longs and go short. Finnies are still to be had and I will be looking to buy MS JPM on any weakness. Jamie Dimon commented today that JPM is having a tough coupple months and man would I love to see a bad quarter to get back in this puppy. Anything bad will turn the market south with the Finnies leading us out with Tech also. GL peeps!
Target buys
MS below $19
JPM below $20
here is the link for the Dimon comment
http://www.reuters.com/article/marketsNews/idUSN2735918020090327
Monday, March 23, 2009
Geithener plan leaked
Looks like Geithener's plan has been leaked on to the internet
He really does not say much more than he did back in Feb and the markets did not like it then so why now??? FAZ SDS getting a beating in the premarket so looks like I further away from profit again. POOP! Still holding because I feel we still have a leg down and the SP is still sitting too high a P/E multiple basis I see it around 660ish.
Futures
DOW +216
NAS +32
SP +24
Sunday, March 22, 2009
Futures looking strong...
Dow +57
SP +10
Nasdaq +12
This market has not changed and I am in settlement currently so I have to sit tight. No trades for me until at least Wednesday.
Saturday, March 21, 2009
Current buy ideas
I am looking to get long after I sell off my short position (below S&P740). Currently I am looking at positioning myself with a bit of diversification and looking to hold long for a bit while keeping small short positions also. I will be buying in 2% increments. And balancing my portfolio into about 5-10% sectors with Financial, Oil, Tech, Industrials, and Biotech/Healthcare.
Buylist:
FCX DO RIG TS HESS CELG GILD JPM MS GS RIMM CSCO DE CAT FWLT
Friday, March 20, 2009
Current Portfolio
Stocks--FAZ 60% SDS 39% DO 1%
Coins-- 28oz Silver bullion(approx value ~$360) 1/10oz platinum (approx value ~$200) and multiple coins and proof sets (approx value ~$500)
Rock on
Buying
I will be looking to buy stocks around a SP of 740-700.
Buys currently :
FCX-- This stock is on fire and I want in on a pullback $30ish
DO-- number two driller with $8 dividend annually (adding around $60)
RIG-- P/E of 4 currently and number one driller ($50-$55)
MS-- investment bank and like it in the teens (below $20)
CSCO-- Cash cow ($15ish)
CELG-- Biotech with Balls ($45)
BUT I will have to sell some FAZ SDS to buy anything and I still have losses to recoup on them and will wait it out. I see alot of downside right now and you have to love when Cramer tells the public to "take some of it off the table". SELL SELL SELL.
Nice Day
Today made about 9%(+$206.30) with FAZ up 15% and SDS up 4% while my small DO position lost 5%. I slept most the day and woke up around 215 and saw some weakness showing in SDS so I sold my entire position and bought it back 3 mins later to drop my avg $0.27. This was something new I tried. I failed on FAZ because I got greedy. Sold it $33.45 and could have bought back at $33.00 but could not pull the trigger fast enough and before you know it, it was back at $33.46 where my buy went in. So pooped that one. Oh well win some, lose some.
S&P closed below 770 which should provide some bearish sentiment to kick back in. We will see how Monday plays out.
Chart Following
Watching the SP500:
Break below 770 and we could spiral down. If it breaks 800, and closes over it I will close my FAZ and SDS as this would be a continuation of the rally. Bernake is speaking around noon. Big Ben has been the saviour as of late. Lets hope tomorrow is another day. Til then...
Break below 770 and we could spiral down. If it breaks 800, and closes over it I will close my FAZ and SDS as this would be a continuation of the rally. Bernake is speaking around noon. Big Ben has been the saviour as of late. Lets hope tomorrow is another day. Til then...
Current Portfolio
FAZ 60% avg $41
SDS 39% avg $95
DO 1% avg $55
2009 (-10%)
I am currently bearish and looking for the S&P to break down under 770 at the open. Futures are trending lower at the moment and look to signal a lower opening and tomorrow is what they call a "Quadruple Witch". I have no clue what the cards hold but I am currently 99% short but looking to get into FCX RIG MS GS JPM and add to DO when the time is right. When that will be I have no clue currently. Rock On.
Investopedia explains:
What Does Quadruple Witching Mean?
A day on which contracts for stock index futures, stock index options, stock options and single stock futures (SSF) all expire. This is similar to the triple witching hour, except that the quadruple witching hour sees also the expiry of SSFs. Quadruple witching days occur on the third Friday of March, June, September and December.
DOW (mini)
FUTURES
FUTURES FAIR VALUE (4.8)
7400.8
7284.0
-68.00
7356.8
7284.0
-72.80
S&P 500
FUTURES
FUTURES FAIR VALUE (0.94)
784.04
772.5
-7.60
781.04
772.5
-8.54
NASDAQ
FUTURES
FUTURES FAIR VALUE (1.96)
1204.21
1203.5
-9.25
1205.46
1203.5
-1.96
SDS 39% avg $95
DO 1% avg $55
2009 (-10%)
I am currently bearish and looking for the S&P to break down under 770 at the open. Futures are trending lower at the moment and look to signal a lower opening and tomorrow is what they call a "Quadruple Witch". I have no clue what the cards hold but I am currently 99% short but looking to get into FCX RIG MS GS JPM and add to DO when the time is right. When that will be I have no clue currently. Rock On.
Investopedia explains:
What Does Quadruple Witching Mean?
A day on which contracts for stock index futures, stock index options, stock options and single stock futures (SSF) all expire. This is similar to the triple witching hour, except that the quadruple witching hour sees also the expiry of SSFs. Quadruple witching days occur on the third Friday of March, June, September and December.
DOW (mini)
FUTURES
FUTURES FAIR VALUE (4.8)
7400.8
7284.0
-68.00
7356.8
7284.0
-72.80
S&P 500
FUTURES
FUTURES FAIR VALUE (0.94)
784.04
772.5
-7.60
781.04
772.5
-8.54
NASDAQ
FUTURES
FUTURES FAIR VALUE (1.96)
1204.21
1203.5
-9.25
1205.46
1203.5
-1.96
Subscribe to:
Comments (Atom)
